Future directions and challenges in harnessing NK cells against Acute Myeloid Leukemia

Acute Myeloid Leukemia (AML) remains one of the most challenging hematological malignancies to treat, with relapse and refractory cases continuing to pose significant hurdles

Three ways to improve participant engagement in your digital clinical trials – Pharmaceutical Technology

Over the past few years, the digitalisation of clinical trials has taken centre stage in clinical research. Accelerated by the rise of decentralised clinical trials

July 4, 2023

The molecular underpinnings by which traumatic brain injury increases Alzheimer’s disease risk

Findings indicate BAG3 modulation after traumatic brain injury may mitigate tau buildup and cognitive deficits, presenting a target for Alzheimer’s prevention.

October 18, 2024

Optimind Pharma – Private Placement | Psychedelic Invest

Toronto, Ontario–(Newsfile Corp. – July 3, 2024) – Optimind Pharma Corp. (CSE: OMND) (the “Optimind” or the “Company”) announces a proposed private placement. The Company

July 8, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.